Munck J N
Département de médecine, institut Gustave-Roussy, Villejuif, France.
Bull Cancer. 1996 May;83(5):352-60.
Etoposide is a major antineoplastic agent which was introduced in the clinic in the 1970s. Its clinical pharmacology was rediscovered at the end of the 1980s because optimal activity was demonstrated to be schedule dependent. The galenic adaptation of an oral form of the molecule led to more extensive studies investigating both the potential advantage of prolonged exposure to the drug and a better bioavailability at low doses. We reviewed current knowledge on clinical applications of continuous oral étoposide in various diseases and discussed the benefit of this mode of therapy over classical intravenous administration in terms of activity, cost and quality of life.
依托泊苷是一种主要的抗肿瘤药物，于20世纪70年代进入临床。20世纪80年代末，其临床药理学被重新发现，因为已证明最佳活性具有给药方案依赖性。该分子口服剂型的药剂学改进促使了更广泛的研究，以探究长期接触该药物的潜在优势以及低剂量时更好的生物利用度。我们回顾了关于连续口服依托泊苷在各种疾病中的临床应用的现有知识，并从活性、成本和生活质量方面讨论了这种治疗方式相对于传统静脉给药的益处。
